The race to target the remaining RAS mutants continues, with over 24 clinical and 70 pre-clinical stage programs striving for first- and best-in-class. Now more than ever, we are witnessing […]

Join us for an exploration of accelerating drug development, streamlining clinical trials and enhancing supply chain efficiency to elevate patient care across the entire value stream at the AI for […]

With Rezdiffra’s approval, GLPs moving into the space, and the wave of promising therapeutics in phrase I-III trials, MASH therapeutics have seen an unprecedented boom in recent months. Don't miss […]